Naval Medical Research Center: Research and Development of Protective Vaccines and Other Countermeasures Against Infectious Disease Agents of Military Importance | N62645 PA 17 1

Opportunity Information: Apply for N62645 PA 17 1

This Department of Defense funding opportunity, issued by the Naval Medical Logistics Command on behalf of the Naval Medical Research Center (NMRC) Infectious Diseases Directorate (IDD-NMRC), is designed to support large-scale research and development aimed at protecting U.S. military forces from infectious disease threats. The central goal is to advance the development and evaluation of both preventive tools (especially vaccines) and therapeutic countermeasures for pathogens that pose significant operational and public health risks to deployed personnel. Rather than funding a single narrow research project, the award is structured to back an organization capable of supplying broad, hands-on support that strengthens and accelerates IDD-NMRC infectious disease research programs.

The scientific scope is wide and focused on agents of clear military importance. Priority areas include malaria caused by Plasmodium falciparum and Plasmodium vivax, bacterial causes of infectious diarrhea, rickettsial pathogens, and a range of emerging and re-emerging viral threats. The viral list specifically includes dengue, MERS-CoV, chikungunya, Zika, and novel influenza viruses. The opportunity also highlights the growing threat of multi-drug resistant bacteria, reflecting the need for countermeasures that remain effective even as antimicrobial resistance increases. Across these areas, the funded work is expected to contribute to the pipeline of candidate vaccines, drugs, diagnostics, or other medical countermeasures, including the kinds of preclinical and clinical evaluation activities needed to assess safety, immunogenicity, and effectiveness.

A key feature of the award is that it is a cooperative agreement, not a traditional grant. That means the government, through IDD-NMRC, is expected to have substantial involvement in the planning and execution of the work. The selected recipient would not operate independently; instead, the awardee would collaborate closely with IDD-NMRC to develop research plans, implement studies, coordinate resources, and support program management. In practice, this type of mechanism typically emphasizes joint decision-making, frequent technical coordination, and shared responsibility for milestones and deliverables, aligning the recipient's capabilities with NMRC mission needs.

The opportunity is structured around providing enabling capacity: manpower, materiel, and clinical trial support. On the personnel side, the award is intended to fund a range of roles that can directly augment government-led research efforts, including scientists, research associates, research assistants, laboratory aides, nurses, clinical trials staff, program managers, and technicians. On the materiel side, funding can support research supplies and equipment needed to conduct laboratory and field studies. For clinical research, the announcement explicitly includes support for clinical trials logistics, including compensation for research subjects, which signals that human studies may be a meaningful component of the supported work and that the recipient must be capable of operating in compliance with applicable clinical research and regulatory requirements.

Eligibility is listed as unrestricted, meaning the competition is open to a broad range of entity types, subject to any additional eligibility details in the full announcement. The opportunity is categorized as discretionary and falls under the Science and Technology and other Research and Development activity category, with CFDA number 12.340. The government anticipated making a single award, with an award ceiling of $27,700,000, indicating a sizable, centralized effort intended to consolidate support under one primary partner organization.

Administrative details provided in the source data show the funding opportunity title as "Naval Medical Research Center: Research and Development of Protective Vaccines and Other Countermeasures Against Infectious Disease Agents of Military Importance" with funding opportunity number N62645 PA 17 1. The announcement was created on June 21, 2017, with an original closing date of July 21, 2017. Overall, the opportunity describes a major collaborative R and D support award meant to expand NMRC's ability to move promising infectious disease countermeasures forward, from laboratory work through clinical evaluation, in direct alignment with military readiness and force health protection priorities.

• The Department of Defense, NAVAL MEDICAL LOGISTICS COMMAND in the science and technology and other research and development sector is offering a public funding opportunity titled "Naval Medical Research Center: Research and Development of Protective Vaccines and Other Countermeasures Against Infectious Disease Agents of Military Importance" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.340.
• This funding opportunity was created on Jun 21, 2017.
• Applicants must submit their applications by Jul 21, 2017. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Each selected applicant is eligible to receive up to $27,700,000.00 in funding.
• The number of recipients for this funding is limited to 1 candidate(s).
• Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.

Apply for N62645 PA 17 1

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: